Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4159 |
Name | skin cancer |
Definition | An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN mut TP53 mut | Sapanisertib | skin cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT04329221 | Phase II | Fluorouracil Calcipotriene + Fluorouracil | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | Not yet recruiting | USA | 0 |
NCT04370587 | Phase I | T3011 | A Clinical Study of T3011 in Patients With Advanced Cutaneous or Subcutaneous Malignancies | Recruiting | USA | AUS | 0 |
NCT04659629 | Phase I | NL-201 | NL-201 in Patients With Relapsed or Refractory Cancer | Completed | USA | CAN | AUS | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |